Navigate
X
    QualityStocks
  • 18 years ago

Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS)

Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS), a clinical-stage biopharmaceutical company, is focused on improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing two potentially complementary agents for the treatment of chronic hepatitis C: ANA598, a non-nucleoside polymerase inhibitor; and ANA773, an oral TLR7 agonist prodrug. For further information, visit the Company’s web site at www.anadyspharma.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…